Christopher W. Ryan

Christopher W. Ryan is a Senior Professor at Oregon Health & Science University specializing in oncology, radiation oncology, and clinical pharmacology. His research focuses on rare tumor immunotherapy, particularly dual anti-CTLA-4 and anti-PD-1 blockade in gynecologic malignancies, pancreatic neuroendocrine neoplasms, and metastatic basal cell carcinoma. He leads the DART SWOG S1609 basket trial, investigating combination checkpoint inhibition across rare cancer subtypes. His recent work includes first-in-human studies of doxorubicin-based click chemistry therapeutics and long-term efficacy trials of pexidartinib for tenosynovial giant cell tumors. His publications appear in the Journal for ImmunoTherapy of Cancer, Cancer Communications, and npj Precision Oncology, reflecting his leadership in precision oncology and rare cancer clinical trials.